Retro Biosciences

Executive Summary

Retro Biosciences is a private biotechnology company founded in 2021 with a bold mission to extend healthy human lifespan by 10 years. Headquartered in San Carlos, California, the company employs a portfolio approach targeting fundamental cellular drivers of aging, including epigenetic reprogramming, autophagy, and mitochondrial function. Retro raised $180 million in Series A financing in 2022, led by Sam Altman and others, positioning it as a well-capitalized player in the longevity space. The company is developing a pipeline of therapies aimed at preventing and reversing age-related diseases, with several programs in preclinical stages. Retro’s strategy combines cutting-edge science with a focus on translational impact, aiming to move rapidly into clinical testing. While the field of longevity is still nascent, Retro’s strong funding and experienced team provide a solid foundation for advancing its platform toward human trials. Retro Biosciences faces significant scientific and regulatory challenges typical of early-stage longevity companies. The company has not yet disclosed specific clinical timelines or lead product candidates, but based on industry norms, IND-enabling studies for its most advanced programs may be underway. If successful, Retro’s therapies could redefine the treatment of age-related conditions, offering disease-modifying rather than symptomatic relief. Investors should monitor progress toward first-in-human trials, as well as any partnerships or milestones that validate the platform. Given the company’s ambitious goals and substantial capital, conviction is moderate but could increase with tangible clinical data.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Longevity Program40% success
• Q4 2026Series B or Strategic Partnership Announcement70% success
• Q3 2026Preclinical Proof-of-Concept Data for Partial Reprogramming60% success